Given the results of the ADCOM on Sarepta, it appears you bet on the public acclimation of the Duchenne drug by the families of the children afflicted. The public approbation of the FDAs needless and questionable delays is what Elite investors can take from the story.
News 
Market Data 
Discover 
AI
